LabCompass

Wael N. Jarjour

Medicine · The Ohio State University

Established · publishing since 1991

Publications

94

Citations

1,499

Est. group size

~2

Recurring co-author estimate

Active years

35

Publishing since 1991

Research summary
AI-generated

Wael N. Jarjour's research focuses on autoimmune rheumatic diseases, particularly systemic lupus erythematosus (SLE), rheumatoid arthritis, and inflammatory muscle diseases (myositis). The work spans laboratory studies of immune cells, autoantibodies, and cell-repair mechanisms in animal and mouse models, as well as clinical and translational studies examining disease markers, imaging, and potential therapies in patients. This research would suit students interested in connecting basic immunology mechanisms to clinical rheumatology problems.

Systemic lupus erythematosus (SLE) and lupus nephritisAutoimmune myopathies and muscle membrane repairRheumatoid arthritis mechanisms and therapyT-cell and B-cell immune regulationExtracellular vesicles and autoantibodies in autoimmune disease

Publication output has fluctuated over the last decade, with a peak in 2020 followed by a decline to lower, more variable annual counts (averaging about 4-5 per year in the last five years).

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 4.4/year recently
2017: 7 publications172018: 9 publications182019: 4 publications192020: 17 publications17202021: 5 publications212022: 8 publications222023: 7 publications232024: 1 publication242025: 6 publications2526
Recent publications
Publishes in
  • Annals of the Rheumatic Diseases×10
  • Frontiers in Immunology×6
  • The Journal of Rheumatology×3
  • Lupus×3
  • bioRxiv (Cold Spring Harbor Laboratory)×3
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile